In this inaugural issue of 2022 we focus in on dealmaking over the course of the pandemic, through a report on the resilience of deal terms during this time, and by taking a look at learnings from the major antibody-drug conjugate alliance deals between AstraZeneca and Daiichi Sankyo, including one negotiated virtually in 2020.
We speak with LifeArc’s Head of Business Development, Linda Bradley, and learn about the medical research charity’s commitment to spend £1.3bn on the sector by 2030 including through translational challenges, much of which is likely to be executed through strategic partnerships.
We hear from Canadian market access subject matter experts on how to launch a drug in Canada, looking particularly at pricing strategies and recent proposals for legislative change. Finally, we cross to the other side of the world for a case study on a rare drug development deal between an Indian CRO and Chinese biopharma company.
Price: